Long-Term Results of a Randomized Trial on Extended Use of High Dose <scp>l</scp>-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia
Andrea Pession(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Maurizio Aricò(University of Bari Aldo Moro), Luca Lo Nigro(Policlinico Universitario di Catania), Edina Magyarosy(Heim Pál Országos Gyermekgyógyászati Intézet), Giuseppe Basso(University of Padua), Carmelo Rizzari(Hôpital Saint-Michel), Maria Grazia Valsecchi(University of Milano-Bicocca), Giuseppe Masera(Azienda Ospedaliera San Gerardo), Willem A. Kamps(Pediatric Oncology Group), Anna van der Does(University of Milano-Bicocca), Elisabeth R. van Wering(Stichting Kinderoncologie Nederland), Franco Locatelli(Bambino Gesù Children's Hospital)
Cited by 202
Related Papers
The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells
|Cell|2011|1.4k
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
|The Lancet Oncology|2009|1k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932